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effectiveness of HLA-B*5801 genotyping compared to no testing. The incidence of 
SJS/TEN was estimated based on case reports from Health Product Vigilance Center 
of Thailand in year 2009. The prevalence of HLA-B*5801 was obtained from Thai 
population reported in dbMHC database, while the association of gene and SJS/TEN 
was based on a meta-analysis. Cost of SJS/TEN management and case-fatality rate 
were derived from National Inpatient Governmental Hospital Database in year 2007. 
We used PG5801 DNA detection kit as a genotyping tool with 100% sensitivity and 
speciﬁ city. We varied genotyping costs and selected values that would make the cost-
effectiveness values being 100,000 or 300,000 THB/life-year gained. One-way sensitiv-
ity analysis was undertaken to identify inﬂ uential parameters. RESULTS: The 
estimated life-years (LY) were 21.9999 and 21.9964 for testing and no testing groups, 
respectively. Setting the genotyping cost as 393 and 1085 THB resulted in a potentially 
cost-effectiveness range of 100,000 and 300,000 THB/LY, respectively. The most 
inﬂ uential parameters were the cost of genotyping and SJS/TEN management. 
CONCLUSIONS: Pharmacogenetic testing for HLA-B*5801 appears to be potentially 
cost-effective if the testing cost falls in the range of 393 and 1085 THB. It was impor-
tant to note that this analysis has not taken into account sequelaes associated with 
SJS/TEN and has not performed based on the societal perspective yet. Policymakers 
should consider our ﬁ ndings for guiding health policy during decision-making process. 
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OBJECTIVES: A US hospital-based economic model was developed to quantify the 
potential cost savings associated with use of an improved non-immunogenic bypassing 
agent with faster bleeding resolution, sustained control and a reduced need for retreat-
ment in order to estimates the inpatient costs for on-demand treatment of bleeds of 
hemophilia patients with inhibitors. METHODS: An Excel-based model patterned the 
inpatient care associated with use of currently available bypassing agents: plasma-
derived activated prothrombin complex concentrate (pd-aPCC) and recombinant 
Factor VIIa (rFVIIa). We used the model to simulate the potential impact of faster 
bleeding resolution associated with an improved bypass agent by examining a realistic 
range of theoretical improvements to the rFVIIa proﬁ le. The model was parameterized 
with treatment-speciﬁ c average resource use, service and pharmacy costs, and source 
admission estimates based on a retrospective analysis of the Premier Perspective™ 
Database, including 1218 inpatient stays with an ICD-9 diagnosis of hemophilia A 
that were identiﬁ ed from 2003–2008. All costs are reported in 2008 USD. RESULTS: 
In the baseline analysis, the average per-patient costs associated with the inpatient 
treatment of hemophilia with inhibitors were slightly lower with rFVIIa as compared 
with pd-aPCC ($78,086 vs. $78,141). The observed cost difference was attributable 
to an observed difference in the percentage of inpatient stays where the patient was 
admitted through the ER associated (rFVIIa: 54%; pd-aPCC: 80%). Exploratory 
sensitivity analyses showed that a potentially faster-acting non-immunogenic treat-
ment (e.g., 10% reduction in length of stay per patient admittance and a 10% reduc-
tion in average duration of bypass agent therapy per patient admittance) could impart 
appreciable incremental cost savings of $7867 (10.1%) compared with pd-aPCC 
treatment. CONCLUSIONS: Our analysis showed that the availability of more effec-
tive bypassing agents with faster bleed resolution may have the potential to confer 
signiﬁ cant inpatient cost savings through reductions in length of stay and duration of 
bypass agent treatment. 
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OBJECTIVES: To examine utilization of health-care services and factor concentrate 
among persons with hemophilia A receiving care at US Hemophilia Treatment Centers 
(HTCs). METHODS: Hemophilia Utilization Group Study (HUGS-Va) is a prospec-
tive multicenter study evaluating burden of illness and cost of care in persons with 
hemophilia A in the United States. Patients or parents of patients < 18 from six HTCs 
completed a standardized interview, including demographics, health insurance cover-
age, barriers to care and treatment pattern. One-year clinical data and two-year dis-
pensing records were abstracted for health care and factor utilization. Annual factor 
use and costs were calculated as the average of two-year data. Generalized linear 
model with Poisson distribution was used to assess the association between factor 
replacement and emergency room visits after adjusting for covariates. RESULTS: Of 
329 participants (50% adults), 68% had severe hemophilia. Ninety-one percent 
reported using health services at least once during the year: 65% had a HTC compre-
hensive evaluation, 33% visited a clinician, 21% had physical therapy, 28% visited 
the emergency room, and 14% were hospitalized. Emergency room visits per person-
year were 58% lower among prophylaxis users (vs.episodic) after adjusting for age, 
employment, and insurance coverage (RR = 0.42, P = 0.002). Patients without inhibi-
tors and severe disease had signiﬁ cantly more factor dispensed (4236 u/kg/yr), com-
pared to those with moderate (1089 u/kg/yr) or mild (582 u/kg/yr) disease (P < 
0.0001). The average factor cost was $165,188 (median: $104,170) per patient-year 
in persons without inhibitors and $700,272 (median: $197,621) in patients with 
inhibitors. CONCLUSIONS: Patients access an array of comprehensive health services 
provided by HTCs. Prophylactic infusion of factor may be associated with decreased 
health-care utilization compared to episodic treatment. 
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OBJECTIVES: Thalassaemia is one of the major public health problems in Thailand. 
Using appropriate iron chelating agents could prevent thalassemia-related complica-
tions which are costly to the health-care system. This study aims to evaluate the 
cost-effectiveness of Deferoxamine (DFO), Deferiprone (DFP), and Desferasirox 
(DFX) in transfusion-dependent thalassaemia patients from the societal perspective. 
METHODS: A Markov model was used to project the life time costs and outcomes 
represented as quality-adjusted life-years (QALYs). Clinical efﬁ cacy and safety of all 
therapeutic options were obtained from a systematic review and clinical trials. Transi-
tion probabilities were derived from literatures while costs were obtained from Thai 
Drug and Medical Supply Information Center, Diagnostic Related Group (DRG) and 
other Thai literatures. Discounting rate of 3% was used. Incremental cost-effectiveness 
ratios were presented as values of year 2009. A series of sensitivity analysis and cost 
effectiveness analysis curve (CEAC) were performed. RESULTS: Compared with DFO, 
using DFP is dominant with cost-savings of US$ 91,107 without QALYs gained. 
Comparing DFX with DFO, the incremental cost was US$ 129,565 and incremental 
QALY was 5.35 with an incremental cost-effectiveness ratio of US$ 22,463. When 
compared to DFP, an incremental cost-effectiveness ratio of DFX was US$ 38,258 per 
QALY. Cost effectiveness analysis curve (CEAC) showed that the probability of DFX 
being cost-effective was 0% when compared with either DFO or DFP, based on the 
cost-effectiveness cut-off value of US$ 2,902 per QALY. When compared to DFP, 
DFX is cost-effective only if DFX cost was lowered from US$ 14.6 to US$ 4 per tablet. 
CONCLUSIONS: Our ﬁ ndings suggest that using DFP is cost-saving when compared 
with the conventional therapy, while using DFX is not cost-effective compared with 
both DFO and DFP. Policymakers and clinicians may consider using such information 
for aiding policy decision-making process in Thailand. 
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OBJECTIVES: To evaluate the cost-effectiveness of deferasirox (DFS) versus deferox-
amine (DFO) in patients with β-thalassaemia major from a Hong Kong (HK) public 
health-care system perspective. METHODS: A Markov model previously developed 
for the United States was adapted to examine the potential cost-effectiveness with DFS 
versus DFO based on lifetime costs and QALYs gained in transfusion-dependent 
β-thalassaemia patients in HK. Patients were assumed to have initiated chelation 
therapy at 3 years of age and have received prescribed dosages of DFS or DFO that 
have been shown to be similarly effective in β-thalassaemia patients. Probabilities of 
complications of iron-overload and death due to poor compliance with chelation 
therapy were estimated using data from recently published studies. Iron chelator 
dosages, costs of administration, and iron overload-related complications were col-
lected from hospital medical records (from January 2004 to December 2009) of 
transfusion-dependent β-thalassaemia patients. Health-state utility values were based 
on a recent study of patients’ preferences for oral versus infusional therapy and pub-
lished literature. A 5% annual discount rate was used. RESULTS: Compared with 
DFO, DFS yielded an additional 3.15 QALYs gained per patient at an additional 
lifetime expected cost of $156,881 USD ($1.22M HKD) per patient; the cost per 
QALY gained was $US49,761 ($388K HKD). The results were sensitive to the esti-
mated infusional administration costs for DFO, the rates of compliance associated 
with oral versus infusional therapy, estimates of the daily dose of DFS, and unit costs 
of each chelator. CONCLUSIONS: Based on the WHO recommended thresholds that 
any incremental cost-effectivess ratio lower than three-times the GDP per capita can 
be considered as cost-effective (GDP of HK in 2009 was $US 29,902), results of this 
study suggest that DFS is probably a cost-effective iron chelator for patients with 
transfusion-dependent β-thalassaemia. 
